Company news
Neurogene Inc. news in 2022
Neurogene Inc.'s news releases, calls and decks from 2022, newest first.
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
December 11, 2022
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
November 13, 2022
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
November 2, 2022
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
August 8, 2022
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
August 2, 2022
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
July 26, 2022
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
May 15, 2022
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
May 8, 2022
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
May 4, 2022
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
April 12, 2022
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
April 6, 2022
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
March 14, 2022
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
March 7, 2022
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
February 28, 2022
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
February 21, 2022
Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
February 2, 2022
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
January 9, 2022
Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
January 9, 2022